In this SOHO Insider roundtable discussion, Charalambos (Babis) Andreadis, MD, MS, professor of clinical medicine at University of California, San Francisco, moderates a discussion on CELLMods in lymphoma.
The panelists include Jason Westin, MD, associate professor in the Department of Lymphoma/Myeloma at University of Texas MD Anderson Cancer Center; Loretta Nastoupil, MD, section chief of indolent lymphoma and director of clinical research at Common Spirit Health; and Swetha Thiruvengadam, MD, assistant clinical professor in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope.
In this video, the group discusses golcadomide’s potential in relapsed or refractory follicular lymphoma, including combinations with rituximab in heavily pretreated patients, ongoing randomized trials, and advantages of novel agents over chemotherapy.
“There’s some data being presented here looking at golcadomide in combination with rituximab in relapsed/refractory follicular lymphoma… efficacy looks quite high. Again, very manageable toxicity profile. So obviously they’re moving it into earlier lines of therapy.” Dr. Nastoupil said on golcadomide plus rituximab in relapsed/refractory follicular lymphoma.
Watch more videos from this discussion.
This video is being brought to you by an education grant by Bristol Myers Squibb.
